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Expanded Abstract 
Citation 
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Background 
Evidence suggests that hypercapnic acidosis may be 
beneficial in patients with acute lung injury, though studies 
have not separated the effects of HA from the effects of 
changes in mechanical ventilation. 
Methods 
Objective: We tested the hypothesis that hypercapnic 
acidosis is associated with reduced mortality rate in patients 
with acute lung injury independent of changes in 
mechanical ventilation. 
Design: Secondary analysis of randomized clinical trial data 
using hypothesis-driven multivariate logistic regression.  
Setting:  Randomized, multiple-center trial comparing 12 
mL/kg to 6 mL/kg predicted body weight (PBW) tidal 
volumes previously published by the National Institutes of 
Health Acute Respiratory Distress Syndrome (ARDS) 
Network. 
Subjects:  861 acute lung injury patients enrolled in a 
randomized, multiple-center trial. 
Intervention: None.  
Measurements and main results: The adjusted odds ratio 
and 95% confidence intervals (CI) for 28-day mortality rate 
associated with hypercapnic acidosis defined as day 1 pH 
<7.35 and PaCO2 >45 mm Hg were 0.14 (95% CI 0.03-0.70, 
p = .016) in the 12 mL/kg PBW tidal volume group and 1.18 
(95% CI 0.59-2.35, p = .639) in the 6 mL/kg PBW tidal 
volume group. Other definitions of hypercapnic acidosis 
spanning a range of magnitudes suggest a dose-response 
association between hypercapnic acidosis and 28-day 
mortality in the 12 mL/kg PBW tidal volume group. None of 
our definitions of hypercapnic acidosis were associated with 
reduction in 28-day mortality in the 6 mL/kg PBW tidal 
volume group. 
Conclusion 
Hypercapnic acidosis was associated with reduced 28-day 
mortality in the 12 mL/kg PBW tidal volume group after 
controlling for co-morbidities and severity of lung injury. 
These results are consistent with a protective effect of 
hypercapnic acidosis against ventilator-associated lung 
injury that was not found when the further ongoing injury 
was reduced by 6 mL/kg PBW tidal volumes. 
Commentary 
Hypercapnic acidosis (HA) is often thought of as a tolerated 
side effect of lung protective ventilation strategies. There is 
a growing body of experimental evidence, however, 
suggesting that HA may be intrinsically protective in 
ventilator-induced lung injury and acute lung injury (ALI) [2-
4] and that buffering HA may be detrimental [5]. Certain 
patient populations, such as those with cardiovascular 
disease or central nervous system injuries, have the 
potential to be harmed by HA. To date, no clinical trial has 
examined the independent effects of HA in patients with 
acute respiratory distress syndrome (ARDS) or ALI.  
In the current study [1], Kregenow and coworkers explored 
the association of HA and mortality in a retrospective 
secondary analysis of 861 subjects with ALI/ARDS enrolled 
in the ARDS Network low vs. high tidal volume trial [6]. HA 
was defined as day 1 pH <7.35 and PaCO2 >45 mm Hg. 
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The authors found that HA was associated with reduced 28-
day mortality in the high tidal volume (12 mL/kg PBW), but 
not low tidal volume (6 mL/kg PBW), group after controlling 
for comorbidities and severity of lung injury. In the high tidal 
volume group, there was an apparent dose-response 
relationship between HA and mortality. The authors 
speculate HA may have mitigated high tidal volume-induced 
lung injury, an effect that was no longer significant when 
lung protective ventilation was utilized. 
As with all observational studies, this study was intended to 
be hypothesis generating and does not prove cause and 
effect. The definition of HA was based on a single day 1 
measurement, rather than by sustained HA over time. As 
noted by the authors, there were too few patients with 
sustained HA to evaluate its effects. Nevertheless, animal 
studies suggest a protective effect of even short duration 
HA. The lack of observed benefit in low tidal volume 
patients may be because there was no effect in this group 
or HA was not extreme enough to exert a physiologic 
benefit [3]. Because the authors did not have data on 
sodium bicarbonate use, dead space ventilation, or 
accurate estimates of CO2 production, this study cannot 
address whether the mechanism of HA is important. 
Recommendation 
A randomized clinical trial of HA in patients with ALI/ARDS 
undergoing lung protective ventilation seems warranted. 
However, greater extremes of HA than seen in the ARDS 
Network low vs. high tidal volume trial will likely be needed 
in order to see a benefit. Until the results of such a trial are 
available, we cannot recommend HA as a specific 
therapeutic goal. For now, HA remains a tolerated side 
effect of lung protective ventilation. 
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